Geron(GERN) Prnewswire·2025-03-25 22:22Core Viewpoint - Securities class action lawsuits have been filed against Geron Corporation for allegedly misleading investors regarding its revenue outlook and product performance during the specified class period from February 28, 2024, to February 25, 2025 [1][2]. Allegations Against Defendants - Defendants allegedly created a false impression of possessing reliable information about Geron's revenue outlook while downplaying risks from seasonality and macroeconomic factors [2]. - Reports regarding the launch success and growth potential of Geron's primary product, RYTELO, were claimed to be overly optimistic and did not reflect the reality of market conditions and competition [2]. - RYTELO reportedly lacked market awareness, hindering Geron's ability to meet the unmet need for the drug among first-line patients and those outside academic settings [2]. - Statements made by the defendants regarding the company's business and prospects were claimed to be materially false and misleading [2]. Lead Plaintiff Process - Investors in Geron have until May 12, 2025, to seek appointment as a lead plaintiff representative for the class, or they may choose to remain absent class members [3]. - The lead plaintiff will represent all class members in directing the litigation and will select counsel to represent the class [3]. Firm Background - Kessler Topaz Meltzer & Check, LLP has a reputation for prosecuting class actions and has recovered billions for victims of corporate misconduct [4].